Which Symptoms Should Be Taken Seriously While Using Weight Loss Injections?

Medications known as weight loss injections may support weight management through different mechanisms, such as appetite control, slowing stomach emptying and regulating blood sugar. Medications containing active ingredients such as semaglutide and tirzepatide have effects associated with GLP-1 receptors. Although they are commonly referred to by brand names such as Ozempic, Wegovy or Mounjaro, the approved indications, doses and conditions of use are not the same for every product.

Nausea, mild abdominal discomfort, constipation, diarrhoea or reduced appetite may occur particularly at the beginning of treatment or during dose escalation. However, medical evaluation is necessary if symptoms are severe, progressively worsen, last for a long time or prevent daily fluid and food intake. People using weight loss injections should know not only which side effects may occur but also which symptoms need to be assessed without delay.

This content is intended for general information. Risks may vary according to the medication used, the dose, accompanying conditions and other medications. In the event of severe or rapidly worsening symptoms, an online consultation should not be awaited; the nearest healthcare facility or emergency department should be contacted.

When Are Weight Loss Injection Side Effects Considered Serious?

Whether a symptom is considered serious does not depend only on the type of side effect experienced. The severity and duration of the symptom, whether the person can drink fluids, whether there is a change in consciousness and whether other symptoms accompany it should also be evaluated. For example, brief and mild nausea is not assessed in the same way as vomiting that continues for hours, prevents fluid intake and causes dizziness.

If symptoms significantly affect daily life, become more severe after each dose or reach an uncontrollable level after a dose increase, tolerance to the medication should be reassessed. It may not be safe for a person to reduce or increase the dose, repeat a dose or switch to another weight loss injection without medical guidance. Such changes should be planned through an endocrinologist’s evaluation.

Symptoms That Should Be Taken Seriously While Using Weight Loss Injections

The following symptoms during weight loss injection use may be associated with the pancreas, gallbladder, kidneys, digestive system, blood sugar or allergic reactions. These symptoms do not always mean that the medication has caused a serious complication; however, they should be evaluated without delay to determine the cause.

Severe and Persistent Abdominal Pain

Pain that starts in the upper or middle abdomen, lasts for a long time, gradually becomes more severe or radiates towards the back should be evaluated for acute pancreatitis. Nausea or vomiting may accompany the pain, but symptoms of pancreatitis may also occur without vomiting.

This type of pain should not be considered ordinary stomach discomfort. Medical evaluation should be obtained before the next dose, particularly if the pain does not improve with rest, prevents eating or makes it difficult for the person to move. If acute pancreatitis is suspected, the decision about whether to continue the medication should be made by a physician.

Upper Right Abdominal Pain, Jaundice or Fever

Gallbladder problems such as gallstones and gallbladder inflammation may develop during the weight loss process. Rapid weight loss may also affect the risk of gallstones in some people. Significant pain in the upper right side of the abdomen, fever, chills, yellowing of the skin or whites of the eyes and pale or clay-coloured stools may suggest a problem involving the gallbladder or bile ducts.

A healthcare facility should be contacted, particularly if these symptoms worsen after meals, last for several hours or occur together with vomiting. Blood tests and imaging methods may be required when gallbladder disease is suspected; a definite diagnosis cannot be made from symptoms alone.

Persistent Vomiting, Diarrhoea and Inability to Drink Fluids

Nausea, vomiting and diarrhoea are among the known digestive side effects of weight loss injections. However, repeated vomiting, inability to drink water or prolonged diarrhoea may cause fluid and electrolyte loss.

Dry mouth, marked thirst, dark urine, reduced urination, weakness, dizziness when standing or a feeling of faintness may be important signs of fluid loss. Earlier evaluation may be needed, particularly in older adults and people with kidney disease or those using blood pressure medications. The FDA states that acute kidney injury associated with vomiting, diarrhoea and fluid loss has been reported with medications containing semaglutide and tirzepatide.

Reduced Urination or Swelling in the Legs

Urinating significantly less than usual, very dark urine or new swelling in the feet, ankles and legs should be evaluated in terms of kidney function and fluid balance. These symptoms do not always indicate kidney damage; however, they should be considered together with fluid loss, other medications and existing kidney conditions.

A reduction in urine output while vomiting or diarrhoea continues is particularly important. Simply trying to drink more water may not be sufficient in this situation. Blood and urine tests may be needed to evaluate kidney function and electrolytes.

Swelling of the Face or Throat and Shortness of Breath

Swelling of the face, lips, tongue, mouth or throat; difficulty breathing or swallowing; widespread hives; severe itching; sudden dizziness or fainting may be signs of a serious allergic reaction. Reactions such as anaphylaxis or angioedema may require emergency treatment.

If any of these symptoms occur, an online doctor consultation should not be awaited and emergency help should be obtained. A person who has previously experienced a serious allergic reaction to semaglutide, tirzepatide or a similar GLP-1 medication should always inform the physician planning the treatment.

Severe or Persistent Stomach and Intestinal Problems

Weight loss injections may slow stomach emptying. This effect may prolong fullness but can cause digestive symptoms to become pronounced in some people. Evaluation is necessary in the event of prolonged vomiting, severe abdominal bloating, progressively worsening abdominal pain, inability to consume food or fluids, or constipation that becomes severe.

People who have previously had delayed stomach emptying known as gastroparesis or another serious digestive condition should inform their physician before treatment. The FDA’s current product information states that some medications containing semaglutide and tirzepatide are not recommended for people with severe gastroparesis.

Sweating, Trembling and Changes in Consciousness

Weight loss injections do not cause hypoglycaemia in every person when used alone. However, the risk of low blood sugar may increase when they are used with insulin or blood sugar-lowering medications in the sulfonylurea group.

Sudden sweating, trembling, intense hunger, palpitations, dizziness, blurred vision, weakness, drowsiness, slurred speech or confusion may be signs of hypoglycaemia. If there is loss of consciousness, a seizure, inability to wake the person or inability to swallow safely, food or drink should not be given by mouth and emergency help should be called. People with diabetes should determine their individual plan for managing low blood sugar with their physician before starting treatment.

New Changes in Vision

In people with type 2 diabetes and a history of diabetic retinopathy, rapid changes in blood sugar may affect the course of eye-related problems. Blurred vision, reduced visual sharpness, new spots in the field of vision or sudden visual changes should not be ignored.

Emergency eye evaluation may be required for vision loss, a curtain-like sensation in the field of vision or a sudden significant change. The treating endocrinologist and an ophthalmologist should also be informed about milder changes.

Rapid Palpitations, Fainting or Chest Pain

A short-term increase in heart rate may occur for different reasons. However, urgent evaluation is needed if persistent or recurring palpitations occur with chest pain, shortness of breath, significant dizziness or fainting.

These symptoms should not be attributed only to the weight loss injection. Fluid loss, low blood sugar, rhythm disorders, low blood pressure or another cardiovascular problem may cause similar complaints. Determining the cause without delay is especially important for people with known heart disease.

A Neck Lump, Hoarseness or Difficulty Swallowing

Official product information for some medications containing semaglutide and tirzepatide includes boxed warnings concerning thyroid C-cell tumours. This risk was observed in animal studies, and its relevance in humans has not been definitively established. Nevertheless, a newly noticed lump or swelling in the neck, persistent hoarseness, difficulty swallowing or unexplained shortness of breath should be evaluated.

People with a personal or family history of medullary thyroid cancer or a diagnosis of Multiple Endocrine Neoplasia Type 2 should inform their physician before starting treatment. Some semaglutide and tirzepatide products should not be used in these situations.

Which Symptoms Require an Emergency Department Visit?

An online endocrinology appointment should not be awaited in the event of symptoms such as inability to breathe, swelling of the face or throat, loss of consciousness, seizures, severe and persistent abdominal pain, chest pain, fainting or sudden vision loss. In these situations, the nearest emergency department should be contacted or emergency help should be called.

In addition to severe symptoms, inability to drink fluids, significantly reduced urination, difficulty standing due to repeated vomiting or rapid deterioration may also require emergency evaluation. Simply waiting for the medication’s effect to wear off after symptoms begin may not be safe.

The main situations that may require emergency evaluation include:

• Difficulty breathing or swallowing
• Swelling of the face, lips, tongue or throat
• Loss of consciousness, seizures or inability to wake
• Severe and persistent abdominal pain radiating to the back
• Chest pain, fainting or significant shortness of breath
• Sudden vision loss
• Uncontrollable vomiting and inability to drink fluids
• Very little urination with marked weakness or dizziness

What Should Be Done When a Symptom Occurs?

The time the symptom started, the day and amount of the most recent dose, whether the dose was recently increased and other accompanying medications should be recorded. Insulin, blood sugar-lowering medications, blood pressure medications and diuretics may be particularly important during the evaluation.

For symptoms that are not severe but continue, contacting the physician who planned the treatment on the same day may be appropriate. Until a physician’s evaluation is completed, taking the dose earlier, doubling a missed dose or using another person’s medication is not safe.

It may be useful to provide the following information during the evaluation:

• Name and dose of the medication used
• Date and time of the last injection
• Time the symptom started and its duration
• Number of episodes of vomiting or diarrhoea per day
• Whether fluids and food can be consumed
• Whether urine output has changed
• Other medications being used
• History of diabetes or kidney, gallbladder, pancreatic or thyroid disease

Who Should Be Monitored More Closely?

A personalised follow-up plan should be created for people who have previously experienced pancreatitis, gallbladder disease, impaired kidney function, serious delayed stomach emptying or diabetic retinopathy. The presence of these conditions does not always mean that a weight loss injection cannot be used; however, it may affect medication selection, the speed of dose escalation and the frequency of monitoring.

The risk of low blood sugar should also be assessed in people with diabetes who use insulin or sulfonylureas. A history of medullary thyroid cancer or MEN 2 may prevent the use of certain medications. Therefore, not only weight and body mass index but also the person’s medical history and all medications used should be reviewed together before treatment.

Why Is Regular Endocrinology Follow-Up Important?

Weight loss injection treatment should not be monitored solely through changes on the scale. The rate of weight loss, digestive tolerance, fluid intake, blood sugar, kidney function and accompanying conditions should be evaluated together. Since every person does not respond to the same dose in the same way, dose escalation should be carried out according to a treatment plan determined by a physician rather than an automatic schedule.

Regular follow-up makes it easier to distinguish mild side effects from symptoms that require more serious evaluation. Whether the medication should be continued, maintained at the same dose, reduced or replaced with an alternative weight management approach can also be planned individually.

Evaluate Your Symptoms With an Online Endocrinologist Through Happ Health

Nausea, digestive problems, blood sugar changes or complaints related to dose tolerance that occur while using a weight loss injection should be evaluated together with the individual’s medical history. Through the Happ Health digital healthcare platform, you can reach an online endocrinologist and obtain a specialist opinion about the medication you use, your dose plan, accompanying conditions and follow-up needs.

An online endocrinology consultation may be used to evaluate non-emergency symptoms and plan the treatment process. In situations such as severe abdominal pain, shortness of breath, loss of consciousness, chest pain, a serious allergic reaction or sudden vision loss, emergency healthcare should be contacted without waiting for an online consultation.

References

• U.S. Food and Drug Administration. Wegovy semaglutide current prescribing information.
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s004lbl.pdf
• U.S. Food and Drug Administration. Zepbound tirzepatide current prescribing information.
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
• U.S. National Library of Medicine MedlinePlus. Semaglutide injection drug information.
• https://medlineplus.gov/druginfo/meds/a618008.html
• U.S. Food and Drug Administration. Mounjaro tirzepatide current prescribing information.
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf